SIGA Technologies focuses on providing TPOXX®, an FDA-approved antiviral for smallpox, primarily through U.S. government contracts including the 19C BARDA contract. Its financial performance over recent years shows strong revenue growth driven by government procurement but with noticeable volatility in income reflecting contract timing and expense dynamics. The company's reliance on government funding presents both a stable revenue base and vulnerability to political and budgetary uncertainties. Regulatory developments, especially from international agencies reviewing TPOXX®'s mpox indication, impose ongoing market access challenges. Capital allocation reflects solid profitability and dividend payouts, while operations hinge on a third-party contract manufacturing model that balances flexibility with supply chain risks.